导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.26% | 2555/4773 |
| 近一周 | -2.23% | 1550/5462 |
| 近一月 | -4.66% | 2632/5421 |
| 近一季 | -11.31% | 3701/5209 |
| 近半年 | -3.93% | 2366/4920 |
| 近一年 | 3.10% | 1997/4366 |
| 近两年 | 59.10% | 1236/2954 |
| 近三年 | 36.47% | 820/2253 |
| 成立以来 | 60.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.49% 2801/4961 |
16.73% 1531/5312 |
- - |
- - |
| 2025 | 28.05% 1513/4813 |
0.07% 1986/3635 |
2.26% 1705/4076 |
22.83% 1606/4524 |
1.87% 1180/4813 |
| 2024 | 15.39% 936/3463 |
2.00% 834/2808 |
-1.62% 1083/3014 |
11.88% 2448/3129 |
2.77% 894/3463 |
| 2023 | -13.14% 1525/2656 |
0.96% 1663/2280 |
-4.40% 1161/2385 |
-4.47% 1147/2515 |
-5.80% 1506/2655 |
| 2022 | -17.90% 637/2207 |
-14.36% 938/1919 |
6.74% 616/2016 |
-11.83% 595/2113 |
1.86% 1113/2208 |
| 2021 | 4.64% 571/1822 |
-2.93% 729/1255 |
9.33% 563/1330 |
-4.40% 705/1466 |
3.14% 470/1822 |
| 2020 | 40.80% 301/1250 |
-7.70% 562/1028 |
17.19% 386/1067 |
13.60% 313/1164 |
14.58% 265/1184 |
| 2019 | 38.03% 321/1092 |
26.82% 377/739 |
-0.04% 203/788 |
0.34% 529/850 |
8.52% 308/918 |
| 2018 | -27.42% 421/834 |
- - |
-9.08% 263/631 |
-2.21% 281/660 |
-11.70% 339/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 平安沪深300指数量化C VS. 长安沪深300非周期A(740101) |